



/

jbwucn@163.com

(0830) 3161702

(0830) 3161702

817

3 319

2001-2003 University of Ulm

1997-1999 /

1985-1990 /

2010. 9-

1994.6-1999.10

1990.9-1999.9

: (*, corresponding author)

1. Ren M, Li R, Luo M, Chen N, Deng X, Yan K, Zeng M, **Wu J***. Endothelial cells but not platelets are the major source of Toll-like receptor 4 in the arterial thrombosis and tissue factor expression in mice. *Am J Physiol Regul Integr Comp Physiol*. 2014;307(7):R901-907.
2. Ji Y, Fish PM, Strawn TL, Lohman AW, **Wu J**, Szalai AJ, Fay WP. C-Reactive Protein Induces Expression of Tissue Factor and Plasminogen Activator Inhibitor-1 and Promotes Fibrin Accumulation in Vein Grafts. *J Thromb Haemost*. 2014;12(10):1667-1677.
3. Li R, Luo M, Ren M, Chen N, Xia J, Deng X, Zeng M, Yan K, Luo T, **Wu J***. Vitronectin regulation of vascular endothelial growth factor-mediated angiogenesis. *J Vasc Res*. 2014; 51:110-117.
4. Li R, Ren M, Chen N, Luo M, Deng X, Xia J, Yu G, Liu J, He B, Zhang X, Zhang Z, Zhang X, Ran B and **Wu J***. Presence of intratumoral platelets is associated with tumor vessel structure and metastasis. *BMC Cancer* 2014; 14:167.

Zhang Z, Chen N, Liu JB, **Wu JB**, Zhang J, Zhang Y, Jiang X. Protective effect of resveratrol against acute lung injury induced by lipopolysaccharide via inhibiting the myd88-dependent Toll-like receptor 4 signaling pathway. *Mol Med Rep*. 2014;10(1): 101-106.

_____. RNA _____.
2014,42(9): 1-4.
7. _____*. [J].
,2013,(8):483-485.
8. Li R, Ren M, Chen N, Luo M, Zhang Z, **Wu J***. Vitronectin increases vascular permeability by promoting VE-cadherin internalization at cell junctions. *PLoS One*. 2012;7(5):e37195.
9. Li R, Ren M, Luo M, Chen N, Zhang Z, Luo B, **Wu J***. Monomeric C-reactive protein alters fibrin clot properties on endothelial cells. *Thromb Res*. 2012;129(5):e251-6.

Zhang Z, Yang Y, Hill MA, **Wu J***. Does C-reactive protein contribute to atherothrombosis via oxidant-mediated release of pro-thrombotic factors and activation of platelets? *Front Physiol*. 2012;3:433.

. Garg N, Goyal N, Strawn TL, **Wu J**, Mann KM, Lawrence DA, Fay WP. Plasminogen activator inhibitor-1 and vitronectin expression level and stoichiometry regulate vascular smooth muscle cell migration through physiological collagen matrices. *J Thromb Haemost.* 2010; 8: 1847-1854.

. Yang Y, Wu X, Gui P, **Wu J**, Sheng JZ, Ling S, Braun P, Davis GE, Davis MJ. α 3 integrin engagement increases BK channel current and Ca^{2+} sensitivity through c-Src mediated channel phosphorylation. *J Biol Chem.* 2010 285(1):131-141.

. **Wu J***. Peng L, McMahon GA, Rabbani AB, Lawrence DA, Fay WP. Recombinant plasminogen activator Inhibitor-1 inhibits intimal hyperplasia. *Arterioscler Thromb Vasc Biol.* 2009; 29(10):1565-1570.

15. Hyder SM, Liang Y, **Wu J**. Estrogen regulation of thrombospondin-1 in human breast cancer cells. *Int. J. Cancer* 2009; 125(5):1045-1053.

16. Hyder SM, Liang Y, **Wu J**, and Welbern V. Regulation of thrombospondin-1 by natural and synthetic progestins in human breast cancer cells. *Endocr Relat Cancer.* 2009;16(3):809-817.

. **Wu J***. Stevenson MJ, Brown JM, Grunz EA, Strawn TL, Fay WP. C-reactive protein enhances tissue factor expression by vascular smooth muscle cells: mechanisms and in vivo significance. *Arterioscler Thromb Vasc Biol.* 2008; 28(4):698-704. Editorial comment.

. Zhou W, Liu Z, **Wu J**, Liu J, Hyder SM, Antoniou E, Lubahn DB. Identification and transcriptional activity characterization of two novel splicing isoforms of human ERR α . *Journal of Clinical Endocrinology & Metabolism* 2006; 91(2):569-579.

. **Wu J**, Liang Y, Nawaz Z, and Hyder SM. Complex agonist-like properties of ICI 182,780 (Faslodex) in human breast cancer cells that predominantly express progesterone receptor-B: Implications for treatment resistance. *International Journal of Oncology* 2005; 27(6): 1647-1659.

20. **Wu J**, Brandt S, Hyder SM. Ligand- and cell-specific effects of signal transduction pathway inhibitors on progestin-induced vascular endothelial growth factor levels in human breast cancer cells. *Molecular Endocrinology* 2005; 19(2):312-326.

. Liang Y, **Wu J**, Hyder SM. p53-dependent inhibition of progestin-induced VEGF expression in human breast cancer cells. *J Steroid Biochem Mol Biol.* 2005; 93(2-5):173-182.

. **Wu J**, Richer J, Horwitz KB and Hyder SM. Progestin-dependent induction of VEGF in human breast cancer cells: preferential regulation by progesterone receptor B. *Cancer Research* 2004; 64(6): 2238-2244.

23. Babiak A, Schumm AM, Wangler, C, Loukas M, **Wu J**, Dombrowski S, Matuschek C, Kotzerke J, Dehio C, Waltenberger J. Coordinated activation of VEGFR-1 and VEGFR-2 is a potent arteriogenic stimulus leading to enhancement of regional perfusion. *Cardiovascular Research* 2004; 61(4):789-795.